

PATIENT INFORMATION SHEET AND INFORMED CONSENT FORM

STUDY TITLE:	A Phase IV, Prospective, Open Label, Multi-Centre Study of Vorasidenib in Indian Adult and Paediatric Participants 12 Years and Older with Grade 2 Astrocytoma and Oligodendroglioma with a Susceptible IDH1 or IDH2 Mutation following Surgery including Biopsy, Sub-Total Resection, or Gross Total Resection
STUDY NUMBER:	SER-VOR-001
SPONSOR:	Servier India Private Limited 1703, 17 th Floor, Crescenzo Business District, 'B' Wing, Plot Nos. C-38/39, 'G' Block, BKC, Bandra (East), Mumbai 400 051, India
PARTICIPANT NUMBER (SCREENING):	
PARTICIPANT INITIALS:	
PRINCIPAL INVESTIGATOR:	RIMPA BASU ACHARI
CONTACT NUMBER OF THE PRINCIPAL INVESTIGATOR:	033-6605-8064-8065
SITE NAME & ADDRESS	TATA MEDICAL CENTER 14, MAJOR ARTERIAL ROAD (EW) NEWTOWN, RAJARHAT KOLKATA-700160

INTRODUCTION

This research study is being conducted and funded by **Servier India Private Limited**, a company that develops medicines. The medicine being studied in this study is called **Vorasidenib**, sold under the brand name **VORANIGO®**.

Vorasidenib is an approved medicine for the treatment of a specific type of brain tumour— **Grade 2 glioma (astrocytoma or oligodendroglioma)**, in adult and paediatric patients aged 12 years and older with a susceptible IDH1 or IDH2 gene mutation, following surgery (including biopsy, sub-total resection, or gross total resection). The approval was granted by the **Central Drugs Standard Control Organisation (CDSCO)**, the national regulatory authority of India for drugs, medical devices, and cosmetics.

Vorasidenib has received regulatory approval but it is still considered an investigational product in the context of this study, as researchers continue to gather more data on its safety and effectiveness in Indian patients. This study has been reviewed and approved by the Drug Controller General of India (DCGI) and an Institutional Ethics Committee (IEC) to ensure it is conducted ethically and safely.

This is a research study, and participation is completely your choice. Before you decide, you need to read and sign this form. The form is meant to help you understand the study and decide if you want to take part. If there are any words or details you do not understand, please ask the doctor or study staff to explain them.

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

You can also take a copy of this form home to think about or discuss with your family or friends before making a decision.

Please feel free to ask as many questions as you need to, before you decide if you want to be in the study. Do not sign this form if you have any questions that have not been answered. Even after you have entered the study, you are free to withdraw at any time you want.

What is the purpose of research?

You are being invited to participate in this study because you have been diagnosed with a type of brain tumour called **Grade 2 glioma**— specifically, either a **Grade 2 astrocytoma** or a **Grade 2 oligodendroglioma**, following surgical intervention. Tests have confirmed that your tumour carries a specific genetic change called a susceptible mutation in the IDH1 or IDH2 gene, which is the target of the medicine being studied.

The brain is the control centre of the body and contains billions of nerve cells that allow us to think, feel, and move. A glioma is a type of brain tumour that starts in the glial cells — the supporting cells of the brain. Grade 2 gliomas grow slowly but can over time become more aggressive. They often cause symptoms such as seizures, headaches, weakness in a part of the body, difficulties with speech or memory, or changes in personality. The IDH1/IDH2 mutation is a specific change in the DNA of tumour cells that causes them to produce a harmful substance called 2-hydroxyglutarate (2-HG), which prevents normal brain cells from maturing and promotes tumour growth.

Vorasidenib is a targeted therapy that works by blocking both the IDH1 and IDH2 mutant proteins simultaneously. By blocking these proteins, vorasidenib reduces the production of 2-HG in tumour cells. This may allow the tumour cells to mature more normally and may slow the growth of the tumour. Importantly, vorasidenib is designed to cross the blood-brain barrier, a protective barrier that controls what enters the brain — making it particularly well suited for treating brain tumours.

The pivotal clinical trial that led to the approval of vorasidenib — the INDIGO trial — showed that vorasidenib significantly prolonged the time before the tumour started growing again (progression-free survival): 27.7 months for patients receiving vorasidenib versus 11.1 months for patients receiving placebo. It also significantly delayed the need for the next cancer treatment.

This Phase IV study is being conducted as a regulatory requirement mandated by CDSCO as a condition of vorasidenib's marketing authorization approval in India. Its goal is to evaluate the safety and effectiveness of vorasidenib specifically in Indian patients with IDH1/IDH2-mutated Grade 2 glioma.. Your participation will help improve future treatment options for others with this type of brain tumour in India.

What should I know about this research study?

You are invited to take part in this research study. You are being asked to participate in this study being conducted in Tata Medical Center [Site name] because you satisfy our eligibility criteria which are:

You MAY be included in this study if:

- a) You are willing and able to sign the informed consent form (or assent, if applicable) and comply with all protocol requirements.
- b) You are 12 years of age or older.

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

- c) You have a histologically confirmed WHO Grade 2 Astrocytoma or Oligodendroglioma: You have a brain tumour diagnosis confirmed by examination of a tissue sample (biopsy or surgical specimen).
- d) You are male, or a non-pregnant, non-lactating female.
- e) You have a confirmed susceptible IDH1 (R132H/C/G/S/L variants) or IDH2 (R172K/M/W/S/G variants) gene mutation, as determined by an accredited laboratory.
- f) You have previously undergone surgery for your brain tumour (including biopsy, sub-total resection, or gross total resection). No prior chemotherapy or radiotherapy for glioma is allowed.
- g) **Your liver function is within acceptable limits as assessed by your study doctor (bilirubin $\leq 1.5 \times \text{ULN}$, AST and ALT at or below ULN, ALP $\leq 2.5 \times \text{ULN}$).**
- h) Your study doctor has determined that treatment with vorasidenib is appropriate for you as per the approved label.
- i) If you are a woman who can become pregnant, you must not be pregnant or breastfeeding at the time of entering the study. You must agree to use a highly effective method of contraception, such as a non-hormonal intrauterine device (IUD), sexual abstinence, or permanent methods like tubal ligation or sterilization, during treatment with VORANIGO® and for at least 3 months after your last dose of study treatment.
- j) If you are a male with a female partner of reproductive potential: you agree to use effective contraception during treatment with VORANIGO® and for 3 months after the last dose.

You will NOT be included in the study if:

- a) You have any contraindications to vorasidenib treatment as per the approved India Prescribing Information.
- b) You have received prior or ongoing radiotherapy and/or chemotherapy (RT-CT) for glioma, including adjuvant or concurrent treatment.
- c) You are pregnant or breastfeeding.
- d) You have any condition that your study doctor deems makes it unsafe for you to participate

You will be one of **15 participants** we plan to enroll in this study across approximately **10 study centers** in India. This is **Phase IV, prospective, open-label** study. All participants receive vorasidenib — there is no placebo or comparison group.

For Paediatric Participants (Aged 12 to 17 Years): For participants who are under 18 years of age, an Informed Consent Form will need to be signed by their parents or Legally Acceptable Representative (LAR) on their behalf. Additionally, the participant will be asked to provide their agreement (assent) to participate in the study, in a separate Informed Assent Form (IAF) which have language according to their age and ability to understand. Participants' parent/LAR and the Investigator will explain the study to paediatric participants in a way that is appropriate for their age.

What are your responsibilities on this study?

While participating in this research study, you will need to:

- Inform your study doctor of all medications, vitamins, and herbal supplements you are currently taking
- Be willing and able to follow the study directions and procedures.
- Tell the study staff honestly about any side effects, symptoms, or other health problems you experience.
- Ask questions as you think of them.
- Tell the investigator or the study staff if you change your mind about staying in the study.

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

- Not use any treatments for cancer, or any other medications that are not advised by your study doctor, without consulting the study doctor first.
- Take vorasidenib tablets exactly as directed: swallow whole with water, at the same time each day, on an empty stomach (no food for at least 2 hours before and 1 hour after each dose). Do not split, crush, or chew the tablets.
- Use an acceptable form of effective non-hormonal birth control during the study from the first day of receiving the study drug until at least 3 months after the last dose of vorasidenib. This applies to all female participants of childbearing potential and males (and their female partners) who could father a child.
- Attend all scheduled study visits and inform the study team in advance if you are unable to attend.

Study Design

This is a Phase IV, Prospective, Open-Label, Multi-Centre study being conducted as a regulatory requirement mandated by CDSCO as a condition of vorasidenib's marketing authorization approval in India.

- **"Phase IV"** means this is a post-marketing study conducted after the medicine has received regulatory approval, to further evaluate its safety and effectiveness in Indian patients.
- **"Prospective"** means participants will be followed forward in time from the time they join the study to collect safety and effectiveness information.
- **"Open-label"** means both you and your study doctor will know which study drug you are receiving.
- **Single treatment group** — all participants receive vorasidenib. There is no placebo or comparison group.

If you decide to take part in this study, you will receive vorasidenib as an oral tablet, taken once daily, at the same time each day, on an empty stomach (no food at least 2 hours before and 1 hour after taking the tablet). Swallow the tablet whole with water. Do not split, crush, or chew the tablet.

- **Adults and paediatric participants weighing ≥ 40 kg: 40 mg tablet once daily**
- **Paediatric participants weighing < 40 kg: 20 mg tablet once daily**

Treatment Cycles: Each treatment cycle lasts 28 days, and you will take vorasidenib every day continuously throughout each cycle with no planned rest periods between cycles. You will receive a total of up to 6 cycles (approximately 6 months of treatment), unless treatment needs to be stopped earlier.

Study Duration: Your total participation in the interventional phase of this study will be approximately 8-9 months, which includes:

- **Screening Phase:** Up to 28 days (to check if you are eligible for the study)
- **Treatment Phase:** 6 cycles of 28 days each (approximately 6 months)
- **Safety Follow-up Visit:** Within 7 weeks after your last dose of study treatment

Post-Trial Access to Vorasidenib:

If you show clinical benefit from vorasidenib at the end of the 6 cycles, you may continue to receive vorasidenib after the study treatment period under Post-Trial Access. This will be provided by the Sponsor free of cost if recommended by the Investigator and approved by the Ethics Committee. Post-trial access will be provided for as long as, in the opinion of the treating investigator, you continue to derive clinical benefit from the investigational study drug, including after completion of any extension phase, if applicable..

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

To continue receiving the investigational study drug after the end of the study, you (or your LAR, if applicable) must provide written consent. In addition, both the investigator and you (or your legal heir, where applicable) must provide written declarations acknowledging that the Sponsor will not be responsible for any claims, liabilities, or injuries arising from the post-trial use of the investigational study drug.

Extension Phase (Optional, Observational):

All participants who complete the study treatment will be invited to participate in an optional Extension Phase, which is observational in nature and will last up to 18 months after completion of the Safety Follow-up Visit. During this phase, you will continue to receive routine clinical care (including monthly liver function tests and brain MRI scans every 6 months). Data collected during this phase will be analysed separately from the main study. Separate written consent will be obtained before you enter this phase.

What are the study procedures?

After you sign this consent form, you will undergo some evaluations to confirm that you meet the medical requirements for participating in the study. It is important to be honest with your study doctor about your health history so that it is safe for you to take part.

Screening Period (up to 28 days):

During this period, your study doctor will assess whether you are eligible to participate. The following assessments will be performed:

- Your eligibility will be confirmed based on the inclusion and exclusion criteria.
- Detailed demographic information, medical/surgical history, and current and prior medications will be recorded.
- A comprehensive physical examination will be done, including neurological examination, and your height, weight, blood pressure, and pulse will be measured.
- A 12-lead electrocardiogram (ECG) will be done to check your heart's electrical activity.
- Your IDH1 or IDH2 mutation status will be confirmed using a banked tissue sample from your surgery (or a fresh biopsy, if no banked sample is available). Note: A new biopsy is NOT required for this study; only confirmation of your existing mutation test result is needed.
- Brain MRI scan will be performed to assess the size and characteristics of your brain tumour (if a clinical MRI scan was performed within 28 days before study entry, it may be used).
- Blood samples will be collected for the following tests:
 - Haematology: haemoglobin, haematocrit, red blood cell (RBC) count, white blood cell (WBC) count and differential (including neutrophils), platelet count.
 - Blood chemistry: sodium, potassium, calcium, magnesium, phosphorus, albumin, glucose, BUN/urea, creatinine, uric acid, LDH
 - Liver Function Tests (LFTs): ALT, AST, ALP, total bilirubin, direct bilirubin, serum albumin
 - Coagulation studies: prothrombin time (PT), aPTT, INR
- A serum pregnancy test (blood) will be done for all women of childbearing potential within 7 days before the first dose.

Treatment Phase Visits (6 Cycles, each 28 days):

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

If you are eligible, you will begin the study treatment. At each Day 1 visit of every cycle (Cycle 1 through Cycle 6), you will come to the study site for detailed assessments. The following procedures will typically be performed:

- Measurement of vital signs (blood pressure, heart rate, temperature) and body weight
- Physical examination (comprehensive at some visits, focused at others)
- 12-lead ECG
- Brain MRI scan (tumour response evaluation): performed at Screening, Cycle 3 Day 1, and Cycle 6 Day 1/End of Treatment — using RANO 2.0 criteria for low-grade glioma
- Blood tests: haematology, serum chemistry, and Liver Function Tests (LFTs)
- Coagulation studies
- Urine pregnancy test for all women of childbearing potential (at Cycle 1 Day 1 and Day 1 of each subsequent cycle)
- Review of any concomitant medications and adverse event monitoring
- Administration of vorasidenib and review of study diary and drug accountability

Liver Function Monitoring Schedule (important): Because vorasidenib is known to cause liver enzyme elevations, liver function tests will be monitored closely:

- Every 2 weeks during the first 2 months of treatment (Cycle 1 Day 1, Day 15; Cycle 2 Day 1, Day 15)
- Additional mid-cycle checks at Cycle 3 Day 15 and Cycle 4 Day 15
- Monthly thereafter (Day 1 of Cycles 5 and 6), and at End of Treatment

If your liver enzyme levels are elevated, your study doctor may temporarily pause your dose, reduce your dose, or permanently stop treatment, as appropriate.

Additional mid-cycle safety visits will be conducted at:

- Cycle 1 Day 8, Day 15, and Day 22 - for adverse event monitoring and study drug accountability
- Cycle 1 Day 15 and Cycle 2 Day 15 - also include LFT and coagulation tests
- Cycle 3 Day 15 and Cycle 4 Day 15 - also include LFT and coagulation tests

End of Treatment (EOT) Visit:

The EOT visit will be conducted within 3 days following your last dose of study treatment (after the final Cycle 6 administration or earlier if you discontinue the study). This visit will include:

- Physical examination and neurological assessment, vital signs, and body weight
- 12-lead ECG
- Blood tests: haematology, serum chemistry, LFTs, and coagulation studies
- Urine pregnancy test (if applicable)
- Brain MRI for tumour response assessment
- Assessment and recording of any adverse events and concomitant medications

Safety Follow-up Visit:

The Safety Follow-up visit will be conducted within 7 weeks after your last dose of study treatment. The procedures include concomitant medication review and adverse event monitoring. This is typically a brief visit or may be conducted by telephone.

Unscheduled Visits: You may be asked to come to the clinic outside of your scheduled visits if your study doctor needs to check your health or manage any side effects.

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

Will the study involve women of childbearing potential?

You must not participate if you are pregnant or breastfeeding a child. If you are a female or male of reproductive potential who is participating in sexual activity that could lead to pregnancy, you must agree to use an approved method of effective non-hormonal birth control for the duration of the study and for at least 3 months following the last dose of vorasidenib. Examples of effective non-hormonal birth control include a condom with spermicide, a diaphragm, or an intrauterine device (IUD). Please discuss your contraception options with your study doctor.

Vorasidenib can make some hormonal contraceptives (such as birth control pills, patches, or hormonal IUDs) less effective. Therefore, you must use a non-hormonal method of contraception while on this study.

You may consider participating if you are surgically sterile or postmenopausal. If you become pregnant during the study, you or your unborn child may be exposed to risks which are currently unknown.

Vorasidenib is not recommended for use during pregnancy, based on findings in animal studies suggesting possible harm to the unborn baby (embryo-fetal toxicity). Breastfeeding is not recommended during treatment with vorasidenib and for 2 months after the last dose.

Fertility: Based on findings in animals, vorasidenib may impair fertility in both females and males of reproductive potential. These effects were not reversible in some animal studies. If you are planning to have children in the future, please discuss this with your study doctor and seek reproductive counselling before starting treatment.

If you are a woman of childbearing potential, your blood (serum) will be tested for pregnancy at screening, and a urine pregnancy test will be conducted on Cycle 1 Day 1 and Day 1 of each subsequent cycle, as well as at the End of Treatment visit. If the test is positive at any time, you will be withdrawn from the study.

What are the possible risks to me from the study?

Like all medicines, vorasidenib may cause side effects. The information below is based on data from the pivotal INDIGO clinical trial and the approved VORANIGO® prescribing information. Not all listed side effects may occur in every patient, and new or unexpected side effects may also sometimes be seen.

In the INDIGO clinical trial, the most common adverse reactions, including laboratory abnormalities, were ALT increased (59.3%), AST increased (45.5%), GGT increased (37.7%), fatigue (36.5%), and diarrhoea (24.6%). The most common Grade 3 or 4 adverse reactions were ALT increased (9.6%), AST increased (4.8%), and GGT increased (3.0%). Serious adverse reactions were reported in 0.6% of patients. Permanent discontinuation of vorasidenib due to an adverse reaction was reported in 3.0% of patients, all related to ALT increase. Dose interruptions occurred in 19.2% of patients; the most common adverse reactions requiring dose interruption were ALT increased (14.4%) and AST increased (6.0%). Dose reductions occurred in 9.6% of patients; the most common adverse reaction requiring dose reduction was ALT increased (7.8%).

Most Common Adverse Reactions:

Laboratory abnormalities (detected through blood tests):

- ALT increased (liver enzyme): Very common — 59.3% of patients; Grade 3/4 in 9.6% of patients
- AST increased (liver enzyme): Very common — 45.5% of patients; Grade 3/4 in 4.8% of patients
- GGT increased (liver enzyme): Very common — 37.7% of patients; Grade 3/4 in 3.0% of patients
- Platelet count decreased: Very common
- ALP increased (alkaline phosphatase): Common (seen in $\geq 1/100$ to $< 1/10$ patients)

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

- Hyperglycaemia (raised blood sugar): Common
- Decreased appetite: Common
- Hypophosphataemia (low phosphate): Common

Non-laboratory (Clinical) Adverse Reactions:

- Fatigue/Asthenia (tiredness or weakness): Very common — 36.5% of patients
- Diarrhoea: Very common — 24.6% of patients
- Abdominal pain (including upper/lower abdomen): Very common

Liver (hepatotoxicity) -Adverse Event of Special Interest in this study:

Vorasidenib can cause significant elevations in liver enzymes (ALT, AST, and GGT). Because of this risk, your liver function tests will be closely monitored every 2 weeks during the first 2 months of treatment, and then monthly for the remaining duration of your study treatment. Depending on the severity of liver enzyme elevation, your doctor may need to pause treatment, reduce your dose, or permanently stop vorasidenib. In most cases, liver enzyme elevations were reversible after dose modification or stopping treatment. In rare cases, serious liver injury including liver failure, liver tissue death (hepatic necrosis), and autoimmune hepatitis was observed in individual patients.

Please report any of the following symptoms to your study doctor immediately: yellowing of the skin or whites of the eyes, dark-coloured urine, pain or discomfort in the upper right side of your abdomen, unusual tiredness, or loss of appetite.

Risks Related to Pregnancy, Breastfeeding, and Fertility:

Vorasidenib is not recommended for use during pregnancy. Based on findings from animal studies, vorasidenib can cause harm to an unborn baby. Breastfeeding is not recommended during treatment with vorasidenib and for 2 months after the last dose. Based on findings in animals, vorasidenib may also impair fertility in both females and males of reproductive potential; these effects were not reversible in some animal studies. Please discuss this with your study doctor before starting treatment if you plan to have children.

Important: Vorasidenib can make some hormonal contraceptives (such as birth control pills) less effective. Therefore, you must use a non-hormonal method of contraception while on this study and for 3 months after the last dose. Please discuss your contraception options with your study doctor.

You must tell the investigator or study staff about all side effects that you have. If you are not honest about your side effects, you may harm yourself by staying in this study. It is possible that other rare side effects could occur which are not described here.

Possible Additional Risks or Discomforts from Study Procedures:

Blood Samples (taken by single needle-sticks):

There may be side effects associated with having blood drawn such as:

- Fainting
- Redness at the needle site
- Pain
- Bruising
- Bleeding
- Infection

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

- Nerve damage
- Blood clots, which may cause inflammation, swelling and pain

If you feel faint, tell the study staff right away.

Brain MRI Scan:

As part of this study, brain MRI scans will be done to check the size and response of your tumour. MRI scans do not involve radiation. However, if a contrast agent (dye) is used, there is a small risk of an allergic reaction. You should inform your doctor if you have any metal implants, pacemakers, or devices in your body. Some participants may feel enclosed or uncomfortable inside the MRI machine — please tell the study staff if this concerns you.

Electrocardiogram (ECG):

The ECG sticky pads used may be cold when applied and sometimes cause some discomfort such as redness or itching. If the hair under the patches needs to be shaved, irritation from shaving also could occur.

Physical Examination:

You may be asked to partially undress for your physical examination. This may feel uncomfortable. You may request that the exam be performed by a qualified staff member of a particular gender, if available. While the study team will try to accommodate your request, it may not always be possible depending on staff availability.

It is possible that other rare or previously unknown side effects could occur which are not described in this document. You must tell the investigator or study staff about all side effects you experience. If you are not honest about your side effects, you may put yourself at risk by remaining in the study.

What are the possible benefits to me from this study?

You may not receive any direct medical benefit from participating in this study. However, there is a possibility that you could benefit if the study treatment (vorasidenib) proves to be effective for your condition. There is no guarantee that your health will improve — your tumour may stay the same or it may worsen. Also, by participating in this study, you will help researchers obtain important information on the safety and effectiveness of vorasidenib in Indian patients, which may benefit others with a similar medical condition in the future.

What will be the possible benefits to other people from this research study?

The results of this study may provide benefits to society through advancement of medical knowledge and/or therapeutic benefit to future participants with IDH1/IDH2-mutated Grade 2 glioma in India. This data will also fulfil the regulatory requirement for a Phase IV study mandated by CDSCO as a condition of vorasidenib's marketing authorization approval in India. The Sponsor of the research, **Servier India Private Limited**, will also benefit from the results of the study, if positive.

Will the study involve any invasive procedures?

Apart from the needle pricks for blood draws, no other invasive or minimally invasive procedures will be performed as part of this study. Brain MRI scans are non-invasive. No new tumour tissue biopsy is required as part of this study only confirmation of your existing IDH1/IDH2 mutation test result (from your prior surgery sample) is required for enrolment.

What would be the total volume of blood collected during the study?

Blood samples will be taken using single needle-sticks at scheduled study visits for safety monitoring, liver function tests, haematology, blood chemistry, coagulation studies, and pregnancy testing (if applicable). The total amount of blood drawn across all study visits during the interventional phase will be approximately 125 mL (approximately 8.5 tablespoons). For comparison, the standard blood donation is about 480 mL (approximately 32 tablespoons or two cups).

In addition, your study doctor may draw extra blood, if needed, to assess your health condition and take appropriate medical decisions regarding your care. The study staff will inform you if this is the case.

Are any treatment alternatives available for me?

If you do not wish to participate, you have the alternative of receiving standard treatment for your condition. Standard management options for Grade 2 IDH-mutant glioma may include observation (watch and wait), radiotherapy, chemotherapy, or other locally available treatments depending on your specific situation. You can speak with your treating doctor or other healthcare professionals regarding the options and alternatives available to you.

Will any confidential information be obtained from me?

Your records from being in this study will be kept private except when sharing the information is ordered by law or as described in this informed consent. You have the right to confidentiality regarding the privacy of your medical information (personal details, results of physical examinations, investigations, and your medical history). By signing this document, you will be allowing the research team investigator (also referred to as study doctor in this document), other study personnel, sponsors, institutional ethics committee, and any person or agency required by law like the Licensing Authority in India to view your data, if required.

The results of clinical tests and therapy performed as part of this research may be included in your medical record. The information from this study, if published in scientific journals or presented at scientific meetings, will not reveal your identity.

A description of this clinical trial may be available on <http://www.ctri.nic.in>, as required by Indian law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time.

Who will be funding the study?

Servier India Private Limited is the Sponsor of the study and is funding this research through payments to the study doctor and the institute. **JSS Medical Research Asia Pacific Private Limited** will be the Contract Research Organization (CRO) assisting the Sponsor throughout the study.

You will not be required to pay for any part of the health assessments (e.g., physical exams, lab tests, or imaging evaluations) done in this study, or for the study medicine.

What should you do in case of injury or a medical problem during this research study?

Your safety is of prime concern to us. If you are injured or have a medical problem because of being in this study, you and/or your nominee should contact one of the people listed at the end of the consent form. Please note that direct payment for loss of wages for participation in this study and expenses other than medical care will not be provided.

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

Will there be any financial compensation for me and/or my nominee due to study-related injury or death?

You and/or your nominee must tell your study doctor immediately if you think you have been injured as a result of participating in the study. In case you have a study related injury, your study doctor will provide medical management as long as required for the injury, the expense of which will be borne by the Sponsor. In the unlikely event that you have a study related injury or study related death, **Servier India Private Limited** will provide financial compensation.

You will be entitled for financial compensation and medical management in the cases of injury or death occurring as per the following:

1. In case the injury occurring to the trial participant is related to the clinical trial, such participant shall also be entitled for financial compensation as per the Rule 39 of New Drugs & Clinical Trial Rules, 2019 and the financial compensation shall be in addition to any expenses incurred on medical management of the trial participant. In case there is no permanent injury, the quantum of compensation shall be commensurate with refuse of wages of the participant.
2. In the case of clinical trial related death, the legal heir of the trial participant shall be provided financial compensation by the sponsor or its representative, as per the Rule 39 of New Drugs & Clinical Trial Rules, 2019 and the financial compensation shall be in addition to any expenses incurred on medical management of the trial participant.
3. The expenses on medical management and financial compensation in the case of clinical trial injury or death of the trial participant shall be borne by the Sponsor of the clinical trial.
4. In the case of an injury occurring to the clinical trial participant, he or she shall be given free medical management as long as required as per the opinion of investigator or till such time it is established that the injury is not related to the clinical trial, whichever is earlier.
5. Any injury or death or permanent disability of a trial participant occurring during clinical trial due to any of the following reasons shall be considered as clinical trial-related:-
 - a. Adverse effect of investigational product
 - b. Violation of the approved protocol, scientific misconduct or negligence by the Sponsor or his representative or the Investigator leading to serious adverse event
 - c. Failure of investigational product to provide intended therapeutic effect. Where, the standard care or rescue medication, though available, was not provided to the participant as per the clinical trial protocol
 - d. Not providing the required standard care, though available to the participant as per clinical trial protocol in the placebo-controlled trial
 - e. Adverse effects due to concomitant medication excluding standard care, necessitated as part of approved protocol
 - f. Adverse effect on a child in-utero because of the participation of the parent in the clinical trial;
 - g. Any clinical trial procedures involved in the study leading to serious adverse event

In the event of a study-related injury or death, you and/or your nominee have/has the right to contact JSS Medical Research Asia Pacific Private Limited for the purpose of making a claim for financial compensation over and above the expenses provided for your participation in the study. The contact details are available in this document under section "Whom should I contact during the study?".

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

LEGAL RIGHTS

You will not lose any of your legal rights by signing this consent form.

Whom should I contact during the study?

For further information/questions, you and/or your nominee can contact any of the following for the purposes mentioned below:

A. For Queries Related to the Study		
Role in the Study	Name	Contact Details
Principal Investigator	Dr. Rimpa Basu Achari Dept. of Radiation Oncology [TATA MEDICAL CENTER 14, MAJOR ARTERIAL ROAD (EW) NEWTOWN,RAJARHAT KOLKATA- 700160]	Ph:033-6605- 8064/8065 Fax:

B. For Queries Related to Your Rights as a Participant in a Clinical Study		
Chairperson, Committee	Ethics Institutional Review Board [TATA MEDICAL CENTER 14, MAJOR ARTERIAL ROAD (EW) NEWTOWN,RAJARHAT KOLKATA- 700160]	Ph :033-6605 7579 Fax:

Will there be any anticipated prorated payment for my participation in the study?

You will be reimbursed for any reasonable travel costs for the visit to the clinic/site facility as a direct result of your participation in this study. You will receive maximum up to INR ___1500___/- per visit.

You will not have any additional costs due to your participation in this study.

How will your decision not to participate in the study affect you?

Your decision not to participate in this research study will not affect your medical care or your relationship with the study doctor or the institution (hospital in which you are being treated). Your study doctor will still take care of you, and you will not lose any benefits to which you are entitled.

Can I decide to stop participating in the study once I start?

Participation in this research is purely voluntary and you have the right to withdraw from this study at any time during the study without giving any reasons. Your decision to refuse participation or to withdraw will not involve any penalty or loss of benefits to which you are otherwise entitled. However, it is advisable that you talk to the research team prior to stopping the treatment. You may be advised about how best to stop the treatment safely. If you withdraw, you may be asked to undergo some additional tests to which you may

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

or may not agree. Though it is advisable that you give the study doctor the reason for withdrawing, it is not mandatory.

Can the study doctor take you off the study?

You may be taken off the study without your consent if you do not follow the instructions of the study doctor or the research team, or if the study doctor thinks that further participation may cause you harm. Other reasons for withdrawal may include worsening of your brain tumour, serious side effects, or other clinical reasons as determined appropriate by your study doctor.

Will I be updated about any new findings related to the study?

If the research team gets any new information during this research study that may affect your decision to continue participating in the study or may raise some doubts, you will be told about that information. If, during the study new information becomes available that may be relevant to your willingness to continue participation in the study, you will be informed immediately and asked to sign a revised informed consent form. You have the right to decide on further participation.

INFORMED CONSENT FORM TO PARTICIPATE IN A CLINICAL TRIAL

Title of the Study	A Phase IV, Prospective, Open Label, Multi-Centre Study of Vorasidenib in Indian Adult and Paediatric Participants 12 Years and Older with Grade 2 Astrocytoma and Oligodendroglioma with a Susceptible IDH1 or IDH2 Mutation following Surgery including Biopsy, Sub-Total Resection, or Gross Total Resection			
Study Number	SER-VOR-001			
Participant's complete Name				
	Title	First Name	Middle Name	Surname
Participant's Initial				
Date of Birth (dd/mmm/yyyy)			Age (in years)	
Participant's Address (complete with city and zip code)	Address:			
	Phone No. (with STD Code): Mobile No.:			
Participant's Education Qualification (please mention complete degree)				
Participant's Occupation (please tick box as appropriate)	Student ☐ Self-employed ☐ Service ☐ Housewife (only for female) ☐ Others:			
Participant's Annual Income (in INR)				
Nominee's Complete Name (an individual or entity who is nominated by the participant for the purpose of receiving compensation in case of study related death)				
	Title	First Name	Middle Name	Surname
Nominee's relationship to the Participant				
Nominee's Address and Contact Details (complete with city and zip code)	Address:			
	Phone No. (with STD Code): Mobile No.:			

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

Please sign or provide your thumb impression (in case you are unable to read or write) on this consent form only after you have had a chance to ask questions and have received acceptable answers to all of your questions. By signing this page, you will be confirming the following statements:

S. No.	Statement	Participant Initials/ Thumb Impression
(i)	I confirm that I have read and understood the information sheet V 1.0 dated 21 Jul 2026 for the above study and have had the opportunity to ask questions.	<i>Participant Initials</i>
(ii)	I understand that my participation in the study is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected.	<i>Participant Initials</i>
(iii)	I understand that the Sponsor of the clinical trial, others working on the Sponsor's behalf, the Ethics Committee and the regulatory authorities will not need my permission to look at my health records both in respect of the current study and any further research that may be conducted in relation to it, even if I withdraw from the trial. I agree to this access. However, I understand that my identity will not be revealed in any information released to third parties or published.	<i>Participant Initials</i>
(iv)	I agree not to restrict the use of any data or results that arise from this study provided such a use is only for scientific purpose(s)	<i>Participant Initials</i>
(v)	I agree to take part in the above study.	<i>Participant Initials</i>

By signing this document, I agree to take part in this study, as set out in this information sheet and consent form.

A.	Participant		
	Complete Name (first name, middle name, last name)	Signature (or Thumb impression)	Date (DD/MMM/YYYY)
B.	Legally Acceptable Representative ☐ ✓ tick if not applicable		
	Complete Name (first name, middle name, last name)	Signature (Thumb impression)	Date (DD/MMM/YYYY)

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited

C.	Study Investigator (per the signed duty delegation log)		
	Complete Name (first name, middle name, last name)	Signature	Date (DD/MMM/YYYY)
D.	Impartial Witness applicable ☐ ☒ tick if not		
	Complete Name (first name, middle name, last name)	Signature	Date (DD/MMM/YYYY)

A copy of the Patient Information Sheet and duly completed, signed/dated Informed Consent Form shall be handed over to the participants and/or his/her attendant (Legally Acceptable Representative).

INVESTIGATOR CERTIFICATE

I certify that all the elements including nature, purpose, possible risks, and rights of the participant for the above study as described in this consent document have been fully explained to the participant. I have also explained the rights of the participant as a participant in this study. In my judgment, the participant possesses the legal capacity to give informed consent to participate in this research and is voluntarily and knowingly giving informed consent to participate.

Signature of the Investigator: _____ Dated: _____

Name of the Investigator: _____

Confidential and Proprietary to JSS Medical Research Asia Pacific Private Limited